Novel Therapies Targeting Endometriosis

Endometriosis is an often painful disorder in which the endometrial glands and stroma grow outside the uterus. The disease affects women’s quality of life and is a common cause of infertility. In this review, we describe promising new developments in the field based on in vitro assays and rodent models, each of which has the potential to be beneficial in the treatment of this disease. We will specifically describe the role of anti-inflammatory drugs, selective estrogen, or progesterone modulators, statins, antiangiogenic agents, and the potential for targeting stem cells as likely methods to hone in and eliminate endometriosis. The most promising of these potential therapies are currently slated for further testing in both rodent and nonhuman primate trials. Similar content being viewed by others

Giudice LC, Kao LC. Endometriosis. Lancet. 2004;364(9447): 1789–1799. Taylor RN, Lebovic DI, Mueller MD. Angiogenic factors in endometriosis. Ann NY Acad Sci. 2002;955: 89–100; discussion 118, 396–406. Krikun G, Lockwood CJ, Paidas MJ. Tissue factor and the endometrium: from physiology to pathology. Thromb Res. 2009; 124(4):393–396. Sharpe-Timms KL, Young SL. Understanding endometriosis is the key to successful therapeutic management. Fertil Steril. 2004;81(5):1201–1203. Rogers PA, D’Hooghe TM, Fazleabas A, et al. Priorities for endometriosis research: recommendations from an international consensus workshop. Reprod Sci. 2009;16(4):335–346. Schindler AE. Pathophysiology, diagnosis and treatment of endometriosis. Minerva Ginecol. 2004;56(5):419–435. Taylor RN, Lundeen SG, Giudice LC. Emerging role of genomics in endometriosis research. Fertil Steril. 2002;78(4):694–698. Wenzl R, Kiesel L, Huber JC, Wieser F. Endometriosis: a genetic disease. Drugs Today (Barc). 2003;39(12):961–972. Kyama CM, Debrock S, Mwenda JM, D’Hooghe TM. Potential involvement of the immune system in the development of endometriosis. Reprod Biol Endocrinol. 2003;1:123. Chegini N. Peritoneal molecular environment, adhesion formation and clinical implication. Front Biosci. 2002;7:e91-e115. Gazvani R, Templeton A. Peritoneal environment, cytokines and angiogenesis in the pathophysiology of endometriosis. Reproduction. 2002;123(2):217–226. Lin YJ, Lai MD, Lei HY, Wing LY. Neutrophils and macrophages promote angiogenesis in the early stage of endometriosis in a mouse model. Endocrinology. 2006;147(3):1278–1286. Barcz E, Rozewska ES, Kaminski P, Demkow U, Bobrowska K, Marianowski L. Angiogenic activity and IL-8 concentrations in peritoneal fluid and sera in endometriosis. Int J Gynaecol Obstet. 2002;79(3):229–235. Drenkhahn M, Gescher DM, Wolber EM, Meyhoefer-Malik A, Malik E. Expression of angiopoietin 1 and 2 in ectopic endometrium on the chicken chorioallantoic membrane. Fertil Steril. 2004;81(suppl 1):869–875. Ferrero S, Ragni N, Remorgida V. Antiangiogenic therapies in endometriosis. Br J Pharmacol. 2006;149(2):133–135. Osteen KG, Yeaman GR, Bruner-Tran KL. Matrix metalloproteinases and endometriosis. Semin Reprod Med. 2003;21(2): 155–164. Osteen KG, Bruner-Tran KL, Ong D, Eisenberg E. Paracrine mediators of endometrial matrix metalloproteinase expression: potential targets for progestin-based treatment of endometriosis. Ann NY Acad Sci. 2002;955: 139–146; discussion 157–138, 396–406. Fazleabas AT, Brudney A, Gurates B, Chai D, Bulun S. A modified baboon model for endometriosis. Ann NY Acad Sci. 2002;955:308–317; discussion 340–302, 396–406. Augoulea A, Lambrinoudaki I, Christodoulakos G. Thoracic endometriosis syndrome. Respiration. 2008;75(1):113–119. Ludwig M, Bauer O, Wiedemann GJ, Diedrich K. Ureteric and pulmonary endometriosis. Arch Gynecol Obstet. 2001;265(3): 158–161. Sasson IE, Taylor HS. Stem cells and the pathogenesis of endometriosis. Ann NY Acad Sci. 2008;1127:106–115. Bulun SE, Cheng YH, Pavone ME, et al. Estrogen receptor-beta, estrogen receptor-alpha, and progesterone resistance in endometriosis. Semin Reprod Med. 2010;28(1):36–43. Simsa P, Mihalyi A, Kyama CM, Mwenda JM, Fulop V, D’Hooghe TM. Selective estrogen-receptor modulators and aromatase inhibitors: promising new medical therapies for endometriosis? Womens Health (Lond Engl). 2007;3(5):617–628. Bruner KL, Matrisian LM, Rodgers WH, Gorstein F, Osteen KG. Suppression of matrix metalloproteinases inhibits establishment of ectopic lesions by human endometrium in nude mice. J Clin Invest. 1997;99(12):2851–2857. Krikun G, Hu Z, Osteen K, et al. The immunoconjugate “icon” targets aberrantly expressed endothelial tissue factor causing regression of endometriosis. Am J Pathol. 2010;176(2):1050–1056. Zamah NM, Dodson MG, Stephens LC, Buttram VC Jr, Besch PK, Kaufman RH. Transplantation of normal and ectopic human endometrial tissue into athymic nude mice. Am J Obstet Gynecol. 1984;149(6):591–597. Bergqvist A, Jeppsson S, Kullander S, Ljungberg O. Human uterine endometrium and endometriotic tissue transplanted into nude mice. Morphologic effects of various steroid hormones. Am J Pathol. 1985;121(2):337–341. Nisolle M, Casanas-Roux F, Donnez J. Early-stage endometriosis: adhesion and growth of human menstrual endometrium in nude mice. Fertil Steril. 2000;74(2):306–312. Bruner-Tran KL, Zhang Z, Eisenberg E, Winneker RC, Osteen KG. Down-regulation of endometrial matrix metalloproteinase-3 and -7 expression in vitro and therapeutic regression of experimental endometriosis in vivo by a novel nonsteroidal progesterone receptor agonist, tanaproget. J Clin Endocrinol Metab. 2006;91(4):1554–1560. Bruner-Tran KL, Eisenberg E, Yeaman GR, Anderson TA, McBean J, Osteen KG. Steroid and cytokine regulation of matrix metalloproteinase expression in endometriosis and the establishment of experimental endometriosis in nude mice. J Clin Endocrinol Metab. 2002;87(10):4782–4791. Olive DL. Role of progesterone antagonists and new selective progesterone receptor modulators in reproductive health. Obstet Gynecol Surv. 2002;57(11 suppl 4):S55–S63. Hemmings R, Rivard M, Olive DL, et al. Evaluation of risk factors associated with endometriosis. Fertil Steril. 2004;81(6): 1513–1521. Bruner-Tran KL, ME M, Osteen KG. Chimeric Models of Experimental Endometriosis (in press) Giudice, LC (editor). 2010. Hammond MG, Oh ST, Anners J, Surrey ES, Halme J. The effect of growth factors on the proliferation of human endometrial stromal cells in culture. Am J Obstet Gynecol. 1993;168(4): 1131–1136; discussion 1136–1138. Harris HA, Bruner-Tran KL, Zhang X, Osteen KG, Lyttle CR. A selective estrogen receptor-beta agonist causes lesion regression in an experimentally induced model of endometriosis. Hum Reprod. 2005;20(4):936–941. Peng J, Sengupta S, Jordan VC. Potential of selective estrogen receptor modulators as treatments and preventives of breast cancer. Anticancer Agents Med Chem. 2009;9(5): 481–499. Stygar D, Muravitskaya N, Eriksson B, Eriksson H, Sahlin L. Effects of SERM (selective estrogen receptor modulator) treatment on growth and proliferation in the rat uterus. Reprod Biol Endocrinol. 2003;1:40. Stratton P, Sinaii N, Segars J, et al. Return of chronic pelvic pain from endometriosis after raloxifene treatment: a randomized controlled trial. Obstet Gynecol. 2008;111(1):88–96. Pickar JH, Yeh IT, Bachmann G, Speroff L. Endometrial effects of a tissue selective estrogen complex containing bazedoxifene/ conjugated estrogens as a menopausal therapy. Fertil Steril. 2009;92(3):1018–1024. Peano BJ, Crabtree JS, Komm BS, Winneker RC, Harris HA. Effects of various selective estrogen receptor modulators with or without conjugated estrogens on mouse mammary gland. Endocrinology. 2009;150(4):1897–1903. Vercellini P, De Giorgi O, Oldani S, Cortesi I, Panazza S, Crosignani PG. Depot medroxyprogesterone acetate versus an oral contraceptive combined with very-low-dose danazol for long-term treatment of pelvic pain associated with endometriosis. Am J Obstet Gynecol. 1996;175(2):396–401. Yap C, Furness S, Farquhar C. Pre and post operative medical therapy for endometriosis surgery. Cochrane Database Syst Rev. 2004;3:CD003678. Hull ML, Charnock-Jones DS, Chan CL, et al. Antiangiogenic agents are effective inhibitors of endometriosis. J Clin Endocrinol Metab. 2003;88(6):2889–2899. Torry DS, Torry RJ. Angiogenesis and the expression of vascular endothelial growth factor in endometrium and placenta. Am J Reprod Immunol. 1997;37(1):21–29. Gargett CE, Rogers PA. Human endometrial angiogenesis. Reproduction. 2001;121(2):181–186. Smith SK. Angiogenesis, vascular endothelial growth factor and the endometrium. Hum Reprod Update. 1998;4(5):509–519. Smith SK. Regulation of angiogenesis in the endometrium. Trends Endocrinol Metab. 2001;12(4):147–151. Ferrara N, Frantz G, LeCouter J, et al. Differential expression of the angiogenic factor genes vascular endothelial growth factor (VEGF) and endocrine gland-derived VEGF in normal and polycystic human ovaries. Am J Pathol. 2003;162(6):1881–1893. Ferrara N, Alitalo K. Clinical applications of angiogenic growth factors and their inhibitors. Nat Med. 1999;5(12):1359–1364. Laschke MW, Elitzsch A, Vollmar B, Vajkoczy P, Menger MD. Combined inhibition of vascular endothelial growth factor (VEGF), fibroblast growth factor and platelet-derived growth factor, but not inhibition of VEGF alone, effectively suppresses angiogenesis and vessel maturation in endometriotic lesions. Hum Reprod. 2006;21(1):262–268. Gescher DM, Haensel A, Meyhofer-Malik A, Malik E. [The importance of angiogenesis for the pathogenesis of endometriosis]. Zentralbl Gynakol. 2003;125(7–8):243–246. Oosterlynck DJ, Meuleman C, Sobis H, Vandeputte M, Koninckx PR. Angiogenic activity of peritoneal fluid from women with endometriosis. Fertil Steril. 1993;59(4):778–782. Sokolov DI, Solodovnikova NG, Pavlov OV, Niauri DA, Volkov NN, Sel’kov SA. Study of cytokine profile and angiogenic potential of peritoneal fluid in patients with external genital endometriosis. Bull Exp Biol Med. 2005;140(5):541–544. Nemerson Y. Tissue factor and hemostasis. Blood. 1988;71(1): 1–8. Belting M, Dorrell MI, Sandgren S, et al. Regulation of angiogenesis by tissue factor cytoplasmic domain signaling. Nat Med. 2004;10(5):502–509. Versteeg HH, Peppelenbosch MP, Spek CA. Tissue factor signal transduction in angiogenesis. Carcinogenesis. 2003;24(6): 1009–1013. Versteeg HH, Ruf W. Emerging insights in tissue factor-dependent signaling events. Semin Thromb Hemost. 2006;32(1): 24–32. Wolberg AS, Monroe DM, Roberts HR, Hoffman MR. Tissue factor de-encryption: ionophore treatment induces changes in tissue factor activity by phosphatidylserine-dependent and -independent mechanisms. Blood Coagul Fibrinolysis. 1999; 10(4):201–210. Versteeg HH, Ruf W. Tissue factor coagulant function is enhanced by protein-disulfide isomerase independent of oxidoreductase activity. J Biol Chem. 2007;282(35):25416–25424. Carmeliet P, Mackman N, Moons L, et al. Role of tissue factor in embryonic blood vessel development. Nature. 1996;383(6595): 73–75. Toomey JR, Kratzer KE, Lasky NM, Stanton JJ, Broze GJ Jr. Targeted disruption of the murine tissue factor gene results in embryonic lethality. Blood. 1996;88(5):1583–1587. Bugge TH, Xiao Q, Kombrinck KW, et al. Fatal embryonic bleeding events in mice lacking tissue factor, the cell-associated initiator of blood coagulation. Proc Natl Acad Sci USA. 1996;93(13): 6258–6263. Hu Z, Sun Y, Garen A. Targeting tumor vasculature endothelial cells and tumor cells for immunotherapy of human melanoma in a mouse xenograft model. Proc Natl Acad Sci USA. 1999; 96(14):8161–8166. Hu Z, Garen A. Intratumoral injection of adenoviral vectors encoding tumor-targeted immunoconjugates for cancer immunotherapy. Proc Natl Acad Sci USA. 2000;97(16): 9221–9225. Hu Z, Garen A. Targeting tissue factor on tumor vascular endothelial cells and tumor cells for immunotherapy in mouse models of prostatic cancer. Proc Natl Acad Sci USA. 2001; 98(21):12180–12185. Du H, Taylor HS. Stem cells and female reproduction. Reprod Sci. 2009;16(2):126–139. Kim JY, Tavare S, Shibata D. Counting human somatic cell replications: methylation mirrors endometrial stem cell divisions. Proc Natl Acad Sci USA. 2005;102(49): 17739–17744. Braundmeier AG, Fazleabas AT. The non-human primate model of endometriosis: research and implications for fecundity. Mol Hum Reprod. 2009;15(10):577–586. Kannan A, Fazleabas AT, Bagchi IC, Bagchi MK. The transcription factor C/EBPbeta is a marker of uterine receptivity and expressed at the implantation site in the primate. Reprod Sci. 2010;17(5):434–443. D’Hooghe TM, Kyama CM, Chai D, et al. Nonhuman primate models for translational research in endometriosis. Reprod Sci. 2009;16(2):152–161. Du H, Taylor HS. Contribution of bone marrow-derived stem cells to endometrium and endometriosis. Stem Cells. 2007; 25(8):2082–2086. Taylor HS. Endometrial cells derived from donor stem cells in bone marrow transplant recipients. JAMA. 2004;292(1):81–85. Du H, Taylor HS. Stem cells and reproduction. Curr Opin Obstet Gynecol. 2010;22(3):235–241. Zhou Y, Gan Y, Taylor HS. Cigarette smoke inhibits recruitment of bone-marrow-derived stem cells to the uterus. Reprod Toxicol. 2011;31(2):123–127. Taylor HS, Fei X. Emx2 regulates mammalian reproduction by altering endometrial cell proliferation. Mol Endocrinol. 2005;19(11):2839–2846. Goldstein JL, Brown MS. Regulation of the mevalonate pathway. Nature. 1990;343(6257):425–430. Zhang FL, Casey PJ. Protein prenylation: molecular mechanisms and functional consequences. Annu Rev Biochem. 1996;65: 241–269. Franzoni F, Quinones-Galvan A, Regoli F, Ferrannini E, Galetta F. A comparative study of the in vitro antioxidant activity of statins. Int J Cardiol. 2003;90(2–3):317–321. Santanam N, Murphy AA, Parthasarathy S. Macrophages, oxidation, and endometriosis. Ann NY Acad Sci. 2002;955:183–198; discussion 119–200, 396–406. Pellegrin S, Mellor H. Actin stress fibres. J Cell Sci. 2007;120(pt 20):3491–3499. Nobes CD, Hall A. Rho, rac, and cdc42 GTPases regulate the assembly of multimolecular focal complexes associated with actin stress fibers, lamellipodia, and filopodia. Cell. 1995;81(1):53–62. Dobreanu M, Dobreanu D, Fodor A, Bacarea A. Integrin expression on monocytes and lymphocytes in unstable angina short term effects of atorvastatin. Rom J Intern Med. 2007; 45(2):193–199. Xu H, Zeng L, Peng H, et al. HMG-CoA reductase inhibitor simvastatin mitigates VEGF-induced “inside-out” signaling to extracellular matrix by preventing RhoA activation. Am J Physiol Renal Physiol. 2006;291(5):F995–F1004. Nasu K, Yuge A, Tsuno A, Narahara H. Simvastatin inhibits the proliferation and the contractility of human endometriotic stromal cells: a promising agent for the treatment of endometriosis. Fertil Steril. 2009;92(6):2097–2099. Sokalska A, Wong DH, Cress A, et al. Simvastatin induces apoptosis and alters cytoskeleton in endometrial stromal cells. J Clin Endocrinol Metab. 2010;95(7):3453–3459. Kyama CM, Overbergh L, Debrock S, et al. Increased peritoneal and endometrial gene expression of biologically relevant cytokines and growth factors during the menstrual phase in women with endometriosis. Fertil Steril. 2006;85(6):1667–1675. Chung HW, Lee JY, Moon HS, et al. Matrix metalloproteinase-2, membranous type 1 matrix metalloproteinase, and tissue inhibitor of metalloproteinase-2 expression in ectopic and eutopic endometrium. Fertil Steril. 2002;78(4):787–795. Sluijter JP, de Kleijn DP, Pasterkamp G. Vascular remodeling and protease inhibition—bench to bedside. Cardiovasc Res. 2006; 69(3):595–603. Schweitzer M, Mitmaker B, Obrand D, et al. Atorvastatin modulates matrix metalloproteinase expression, activity, and signaling in abdominal aortic aneurysms. Vasc Endovascular Surg. 2010;44(2):116–122. Porter KE, Turner NA. Statins for the prevention of vein graft stenosis: a role for inhibition of matrix metalloproteinase-9. Biochem Soc Trans. 2002;30(2):120–126. Bruner-Tran KL, Osteen KG, Duleba AJ. Simvastatin protects against the development of endometriosis in a nude mouse model. J Clin Endocrinol Metab. 2009;94(7):2489–2494. Foyouzi N, Berkkanoglu M, Arici A, Kwintkiewicz J, Izquierdo D, Duleba AJ. Effects of oxidants and antioxidants on proliferation of endometrial stromal cells. Fertil Steril. 2004;82(suppl 3):1019–1022. Piotrowski PC, Kwintkiewicz J, Rzepczynska IJ, et al. Statins inhibit growth of human endometrial stromal cells independently of cholesterol availability. Biol Reprod. 2006;75:107–111. Esfandiari N, Khazaei M, Ai J, et al. Effect of a statin on an in vitro model of endometriosis. Fertil Steril. 2007;87(2): 257–262. Sharma I, Dhawan V, Mahajan N, Chand Saha S, Dhaliwal LK. In vitro effects of atorvastatin on lipopolysaccharide-induced gene expression in endometriotic stromal cells. Fertil Steril. 2010 94(5):1639–46.e1. Wassmann S, Laufs U, Muller K, et al. Cellular antioxidant effects of atorvastatin in vitro and in vivo. Arterioscler Thromb Vasc Biol. 2002;22(2):300–305. Weber MS, Stuve O, Neuhaus O, Hartung HP, Zamvil SS. Spotlight on statins. Int MS J. 2007;14(3):93–97. Greenwood J, Steinman L, Zamvil SS. Statin therapy and autoimmune disease: from protein prenylation to immunomodulation. Nat Rev Immunol. 2006;6(5):358–370. Aljada A, O’Connor L, Fu YY, Mousa SA. PPAR gamma ligands, rosiglitazone and pioglitazone, inhibit bFGF- and VEGF-mediated angiogenesis. Angiogenesis. 2008;11(4): 361–367. Imamoto E, Yoshida N, Uchiyama K, et al. Inhibitory effect of pioglitazone on expression of adhesion molecules on neutrophils and endothelial cells. Biofactors. 2004;20(1):37–47. Herington JL, Crispens MA, Carvalho-Macedo AC, et al. Development and prevention of postsurgical adhesions in a chimeric mouse model of experimental endometriosis. Fertil Steril. 2011;95(4):1295–1301. Mathur SP. Autoimmunity in endometriosis: relevance to infertility. Am J Reprod Immunol. 2000;44(2):89–95. Author information Authors and Affiliations Corresponding author Rights and permissions About this article Cite this article Taylor, H.S., Osteen, K.G., Bruner-Tran, K.L. et al. Novel Therapies Targeting Endometriosis. Reprod. Sci. 18, 814–823 (2011). https://doi.org/10.1177/1933719111410713 Published: Issue date: DOI: https://doi.org/10.1177/1933719111410713